Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

HIV market to surpass $32 billion across 7MM in 2033, forecasts GlobalData

The human immunodeficiency virus (HIV) market across the seven major markets (7MM*) is forecast to grow at a compound annual growth rate (CAGR) of 1.9% from $26.5 billion in 2023 to $32.1 billion in 2033, forecasts GlobalData, a leading data and analytics company. GlobalData’s report, “Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast,” reveals that market […]
Read more

GLP-1R agonists poised to redefine chronic disease treatment beyond diabetes and obesity, says GlobalData

GLP-1 receptor agonists, once focused on treating diabetes and obesity, are now emerging as potential treatments for a broader range of chronic conditions, including Alzheimer’s disease. As evidence builds around their wider therapeutic benefits, particularly in targeting insulin resistance, drug developers are accelerating efforts to expand their use and potentially transform how multiple high-burden diseases […]
Read more

Three CAR-T therapies to capture over 70% of T-Cell immunotherapy market in 2025, forecasts GlobalData

T-cell immunotherapies (TCI) are redefining cancer care, with chimeric antigen receptor T-cell (CAR-T) therapies witnessing significant momentum. In 2025, just three drugs- Carvykti by Legend Biotech, Yescarta by Gilead Sciences, and Breyanzi by Bristol-Myers Squibb (BMS)– are expected to capture over 70% of the global T-cell immunotherapy market, according to GlobalData, a leading data and […]
Read more

Finerenone continues to impress in diabetic kidney disease space, says GlobalData

In a recent study conducted by Navaneethan and colleagues and published in the International Society of Nephrology, the cardiovascular and kidney benefits of Bayer’s Kerendia (finerenone) are maintained regardless of acute changes in estimated glomerular filtration rate (eGFR) following treatment initiation in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). This comprehensive […]
Read more

Shionogi’s cefiderocol shows improved outcomes with early use in treating gram-negative infections, reports GlobalData

Japan-based Shionogi has shared new real-world evidence showing its antibiotic cefiderocol leads to better outcomes when used early to treat serious gram-negative bacterial infections. Presented at European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2025 conference in Vienna, the Retrospective Cefiderocol Chart Review (PROVE) study found that earlier use of cefiderocol, rather than […]
Read more

Global divide emerges among physicians over patient choice in biologics vs. biosimilars, reveals GlobalData

Physician attitudes toward patient choice between the use of biologics and biosimilars vary widely across global markets, revealing deep-rooted cultural and systemic differences. While nearly half of (49%) physicians support patient involvement in treatment decisions, enthusiasm ranges from strong backing in China to notable skepticism in Germany and France—underscoring the growing but uneven shift toward […]
Read more

Innovent’s Sycume to transform thyroid eye disease treatment landscape in China and Asia, says GlobalData

Innovent Biologics has recently received approval for Sycume (teprotumumab biosimilar) to treat thyroid eye disease (TED) in China. It is the country’s first insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody approved for TED by the National Medical Products Administration (NMPA). It represents a significant breakthrough and has the potential to transform the standard of […]
Read more

COPD market to surpass $30.2 billion in 7MM in 2033, driven by biologics and precision medicine, forecasts GlobalData

The chronic obstructive pulmonary disease (COPD) market across the seven major markets (7MM*), is projected to grow from $11.6 billion in 2023 to $30.2 billion in 2033, representing a compound annual growth rate (CAGR) of 10%, driven by the entry of biologics into the treatment landscape and the continued integration of precision medicine approaches, forecasts […]
Read more

Remegen eyes competitive DMT market as telitacicept shows promise in gMG, says GlobalData

At the recently held 2025 American Academy of Neurology (AAN) meeting, Remegen presented positive Phase III results for telitacicept in patients with AChR+ or MuSK+ generalized myasthenia gravis (gMG). The B cell-targeting therapy demonstrated a favorable efficacy and safety profile over 24 weeks, showing clinically meaningful improvement. These findings position telitacicept as a potential challenger […]
Read more

OX40 inhibitors may transform atopic dermatitis landscape, says GlobalData

The atopic dermatitis (AD) treatment landscape is witnessing intensified competition with several novel therapies nearing market entry. While biologics like dupilumab have already transformed care, emerging drug classes such as OX40 inhibitors are showing promise in clinical trials. Their potential for long-lasting efficacy and favorable safety profiles may significantly advance treatment options for moderate-to-severe AD […]
Read more

Axsome Therapeutics’ AXS-05 challenges current standard of care as promising non-antipsychotic for Alzheimer’s agitation, says GlobalData

At the recently held American Academy of Neurology (AAN) 2025 annual meeting, Axsome Therapeutics presented promising data for AXS-05 (bupropion + dextromethorphan) in treating agitation associated with Alzheimer’s disease (AD). With a novel, non-antipsychotic mechanism and a favorable safety profile, AXS-05 addresses a critical unmet need in managing distressing behavioral symptoms, potentially reshaping the current […]
Read more

DHTs promise detection of disease progression in early PD patients receiving symptomatic treatment, says GlobalData

At the recently held AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases, Roche outlined the effectiveness of digital health technologies (DHTs) in providing more sensitive measures of disease progression in early Parkinson’s disease (PD). There are no pathological or imaging-based biomarkers to measure a PD patient’s progression. Instead, physicians rely on clinical examinations and […]
Read more

Roche’s Brainshuttle technology promises next generation of amyloid beta mAbs, says GlobalData

At the recently held AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases, Roche presented interim trial data for its novel anti-amyloid monoclonal antibody (mAb), trontinemab, to clinically validate its proprietary Brainshuttle technology for the treatment of prodromal or mild to moderate Alzheimer’s disease (AD). The presentation showcased promising results from early clinical experience, with […]
Read more
1 … 8 9 10 11 12 … 108